pharmaceutical daily

June 19, 2019 Off

Natural ingredients show beneficial effects on cardiovascular health and sports performance

Euromed, a Spain-based producer of standardized herbal extracts and natural active substances for pharmaceutical, nutraceutical and cosmetic industries, said Wednesday that, according to a recently published randomised, double-blind, placebo-controlled study, supplementation with Euromed’s natural extracts Pomanox™ and Mediteanox™ could help to maintain a healthy blood pressure, endothelial function and levels of circulating oxidised low-density lipoprotein cholesterol (oxLDL).

June 19, 2019 Off

Lynparza approved in Japan for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer

By Dino Mustafić

AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .

June 19, 2019 Off

Boys and Girls Clubs of Canada Join the Fight Against the Opioid Crisis in National Partnership with Adapt Pharma Canada

By Dino Mustafić

Boys and Girls Clubs of Canada (BGCC) has partnered with NARCAN Nasal Spray manufacturers, Adapt Pharma Canada, in the continued fight against the devastating fallout of Canada’s opioid crisis.

June 19, 2019 Off

Pharmaceutical Executive Releases 19th Annual Pharma50 for 2019

By BusinessWire

The list features the top 50 biopharma companies by 2018 prescription sales CRANBURY, N.J.–(BUSINESS WIRE)–#pharma—Pharmaceutical Executive, a multimedia platform for…

June 19, 2019 Off

Medison Issues Open Letter to Knight Therapeutics Shareholders Urging Jonathan Goodman to Build Real Business during the Grace Period Knight Received

By BusinessWire

PETACH TIKVA, Israel–(BUSINESS WIRE)–Medison Biotech (1995) Ltd. (“Medison”), which together with its affiliates owns more than 10.4 million shares or…

June 19, 2019 Off

2018 Market Spotlight: Norovirus – Key Pipeline Drugs, Clinical Trials, Probability of Success, Key Upcoming Events, and an Epidemiological Overview – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Norovirus” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Norovirus market,…

June 19, 2019 Off

Randstad Japan Names PPD-SNBL a Top-Five Growth Business and Desirable Employer

By BusinessWire

Clinical-development joint venture commended for staff growth and retention WILMINGTON, N.C. & TOKYO–(BUSINESS WIRE)–PPD-SNBL, the joint venture of Pharmaceutical Product…

June 19, 2019 Off

Clinical Results of Fully Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings

By BusinessWire

IASO Biotherapeutics unveils an innovative new CAR-T therapy for the treatment of relapse/refractory multiple myeloma and the retreatment of previously…

June 19, 2019 Off

Global HPLC Systems and Accessories Market Analysis, Trends, and Forecasts Report 2019: Focus on Pharma & Biotech, Academia, CROs, Chemical, Agriculture, Clinical, Government, and Others – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “HPLC Systems and Accessories: Global Market Analysis, Trends, and Forecasts” report has been added to ResearchAndMarkets.com’s offering. This…

June 19, 2019 Off

CARsgen Therapeutics’ leading candidate gets FDA IND clearance

By Dino Mustafić

One of CARsgen Therapeutics’ leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the treatment of patients suffering from relapsed/refractory multiple myeloma (rrMM), has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA).